Perception Neuroscience, an ATAI Life Sciences company, is a biopharmaceutical company developing arketamine therapy for neuropsychiatric diseases. Perception’s mission is to provide substantially more effective treatment solutions to serious psychiatric disorders.

Perception Neuroscience’s lead product is the NMDA antagonist arketamine (PCN 101), a single isomer of ketamine. Arketamine belongs to a new generation of glutamate receptor modulators with the potential for rapid acting antidepressant (RAAD) activity and anti-suicidal effects. These new RAAD drugs are expected to be more efficacious than current FDA-approved anti-depressant therapies, which often take weeks to achieve maximal effectiveness, if at all. Ketamine, as described in the journal Science “is arguably the most important discovery in half a century” of research in depression, and arketamine is anticipated to differentiate robustly from other development stage RAAD’s on both efficacy and safety.

Perception Neuroscience was founded on the basis of strong evidence, both in animal models as well as in normal human volunteers, that arketamine has an improved profile versus both racemic ketamine, as well as esketamine, both in terms of efficacy as well as safety. Clinical trials will begin in early 2019.

Perception Neuroscience is based in New York City and also has an Office in Melbourne, Australia.

Home | Careers | Contact

Christian Angermayer


Strategy and investor relations

Lars Wilde


Advising on drug discovery and compound sourcing

Florian Brand

Co-Founder and Chief Executive Officer

Executing drug development and operations

Simon Seibold


Investments and business development

Philipp Schreiber


Drug discovery and compound sourcing

ATAI is supporting the revival of treatments with prior evidence in humans, such as psilocybin and ketamine, in fighting mental health disorders

Depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder and other psychiatric conditions are increasingly becoming a burden for patients, families and societies.

We believe that

ATAI is leveraging the potential of artificial intelligence (AI) and big data analytics to optimize and accelerate the drug development process

Technological innovation will enable us to consolidate and make sense of vast amounts of previously inaccessible data.

We believe that

Matthias Luz, MD

Chief Medical Officer

Developing clinical strategy for lead compounds

Srinivas Rao, MD, PhD

Chief Scientific Officer

Advance the science into clinical evaluation

Danny Talati

Lead, Business Development

Compound sourcing and evaluating